Low-dose epirubicin inhibits ezrin-mediated metastatic behavior of breast cancer cells

Tumori

Volumn 97, Issue 3, 2011, Pages 400-405

  Ma, Li ^a   Liu, Yue Ping ^a   Geng, Cui Zhi ^a   Xing, Ling Xiao ^a   Zhang, Xiang Hong ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cell migration; Epirubicin; Ezrin

Indexed keywords

EPIRUBICIN; EZRIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; METASTASIS; MIGRATION INHIBITION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL MOVEMENT; CELL PROLIFERATION; CYTOSKELETAL PROTEINS; DISEASE PROGRESSION; EPIRUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UP-REGULATION;

EID: 79960850875     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/912.10041     Document Type: Article

References (20)

1. Cheng L, Itoh K, LemmonV: L1-mediated branching is regulated by two ezrin-radixin-moesin (ERM)-binding sites, the RSLE region and a novel juxtamembrane ERM-binding region. J Neurosci, 25: 395-403, 2005. (Pubitemid 40105609)
2. Rasmussen M, Alexander RT, Darborg BV, Mobjerg N, Hoffmann EK, Kapus A, Pedersen SF: Osmotic cell shrinkage activates ezrin/radixin/moesin (ERM) proteins: activation mechanisms and physiological implications. Am J Physiol Cell Physiol, 294: 197-212, 2008.
3. Heiska L, Carpén O: Src phosphorylates ezrin at tyrosine 477 and induces a phosphospecific association between ezrin and a kelch-repeat protein family member. J Biol Chem, 280: 10244-10252, 2005. (Pubitemid 40395880)
4. Swanson KA, Crane DD, Caldwell HD: Chlamydia trachomatis species-specific induction of ezrin tyrosine phosphorylation functions in pathogen entry. Infect Immun, 75: 5669-5677, 2007. (Pubitemid 350207803)
5. Ilani T, Khanna C, Zhou M, Veenstra TD, Bretscher A: Immune synapse formation requires ZAP-70 recruitment by ezrin and CD43 removal by moesin. J Cell Biol, 179: 733-746, 2007. (Pubitemid 350146258)
6. Stapleton G, Malliri A, Ozanne BW: Downregulated AP-1 activity is associated with inhibition of protein-kinase-c-dependent CD44 and ezrin localisation and upregulation of PKC theta in A431 cells. J Cell Sci,115: 2713-2724, 2002. (Pubitemid 34846512)
7. Barreiro O, Yáñez-Mó M, Serrador GM, Montoya MC, Vicente- Manzanares M, Tejedor R, Furthmayr H, Sanchez- Madrid F: Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J Cell Biol, 157: 1233-1245, 2002. (Pubitemid 34847793)
8. Ohtani K, Sakamoto H, Rutherford T, Chen Z, Kikuchi A, Yamamoto T, Satoh K, Naftolin F: Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett, 179: 79-86, 2002. (Pubitemid 34195656)
9. Chen Z, Fadiel A, Feng, Y, Ohtani K, Rutherford T, Naftolin F: Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor. Cancer, 92: 3068-3075, 2001. (Pubitemid 33136203)
10. Zeng H, Xu L, Xiao D, Zhang H, Wu X, Zheng R, Li Q, Niu Y, Shen Z, Li E: Altered expression of ezrin in esophageal squamous cell carcinoma. J Histochem Cytochem, 54: 889-896, 2006. (Pubitemid 44106866)
11. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G: Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med, 10: 175-181, 2004. (Pubitemid 38524888)
12. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ: The membrane- cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med, 10: 182-186, 2004. (Pubitemid 38524889)
13. Brown C, Pan X, Hassid A: Nitric oxide and C-type atrial natriuretic peptide stimulate primary aortic smooth muscle cell migration via a cGMP-dependent mechanism: relationship to microfilament dissociation and altered cell morphology. Circ Res, 84: 655-667, 1999. (Pubitemid 29157333)
14. Wu Y, Zhou BP: New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai), 40: 643-650, 2008. (Pubitemid 352009085)
15. Cavalli LR, Urban CA, Dai D, de Assis S, Tavares DC, Rone JD, Bleggi-Torres LF, Lima RS, Cavalli IJ, Issa JP, Haddad BR: Genetic and epigenetic alterations in sentinel lymph nodes metastatic lesions compared to their corresponding primary breast tumors. Cancer Genet Cytogenet, 146: 33-40, 2003. (Pubitemid 37117432)
16. Bretscher A, Edwards K, Fehon RG: ERMproteins andmerlin: integrators at the cell cortex. Nat Rev Mol Cell Biol, 3: 586-599, 2002.
17. Bretscher A: Regulation of cortical structure by the ezrin-radixin-moesin protein family. Curr Opin Cell Biol, 11: 109-116, 1999.
18. Ceccarelli DF, Song HK, Poy F, Schaller MD, Eck MJ: Crystal structure of the FERM domain of focal adhesion kinase. J Biol Chem, 281: 252-259, 2006. (Pubitemid 43671184)
19. Yu Y, Davicioni E, Triche TJ, Merlino G: The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res, 66: 1982-1989, 2006.
20. Musiał J, Sporny S, Nowicki A: Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer. Pol J Pathol, 58: 235-243, 2007. (Pubitemid 351428300)